- Initiated final IND/CTA enabling studies for lead in vivo gene editing program PBGENE-HBV; expect to submit IND and/or CTA in 2024 - Completed licensing agreements to monetize divested CAR T assets with Imugene , TG Therapeutics and Caribou Biosciences including nearly $50 million in upfront and